TTrialPathMatch Me to Trials
← Back to trials
RecruitingChondral DefectOsteochondritis Dissecans (OCD)Articular Cartilage Defect

A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

Eligible age

10–17 yrs

Accepts

All genders

Locations

10 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of participants aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.

Sponsor: Vericel Corporation

You may qualify if…

  • ✓ Age 10 to 17 years at the time of planned randomization
  • ✓ Symptomatic cartilage or osteochondral defects
  • ✓ One or more International Cartilage Repair Society (ICRS) Grade III or IV chondral or unsalvageable osteochondral defects located on the femoral condyles and/or trochlea amenable to treatment with the surgical procedure determined at randomization (MACI or microfracture).
  • ✓ 1. Concurrent ICRS Grade I and II defects are acceptable on the tibia if they remain untreated (or are treated with debridement only) at the time of study treatment.
  • ✓ 2. Participants with a potentially re-attachable osteochondral fragment, identified by magnetic resonance imaging (MRI) and that has not previously been repaired, may be consented to the study and undergo baseline assessments per protocol and prior to confirmatory arthroscopy (Visit 2). At arthroscopy, an attempt will be made to reattach the osteochondral fragment. If this is successful, the participant will be excluded from the study and deemed an intra-operative screen failure. If the attempted reattachment fails and no other exclusion criteria apply, the participant may continue in the PEAK study: a MACI biopsy will be taken, the participant will be randomized and treated per protocol.
  • ✓ At least 1 defect size ≥1.5 cm2 on the patella, femoral condyles and/or the trochlea; defects include OCD lesions with a bone lesion depth of ≤6 mm and does not require a bone graft.
  • ✓ Salvageable OCD lesions must have failed prior conservative and a reparative treatment, and the participant still experiences pain associated with the osteochondral lesion. Participants with defects as a result of trauma or unknown etiology are eligible regardless of prior treatments.
  • ✓ Stable target knee (i.e., anterior and posterior cruciate ligaments should be free of laxity as well as stable and intact). Ligament repair or reconstruction procedures are allowed prior to screening arthroscopy.

You may not qualify if…

  • ✕ Any surgery on the target knee joint within 6 months prior to Screening (not including diagnostic arthroscopy)
  • ✕ Previous investigational drug or device use within 3 months prior to Screening
  • ✕ Avascular necrosis of the target knee (other than potential OCD lesion to be treated)
  • ✕ Participants with uninvolved open growth plates where the surgery necessitates crossing the growth plate, or where the depth of the lesion crosses the growth plate
  • ✕ ICRS Grade III or IV chondral or unsalvageable osteochondral defects located on the tibia or any lesion that is bipolar to the index lesion
  • ✕ Malalignment requiring concurrent osteotomy to correct tibial-femoral or patella-femoral alignment (prior guided growth treatment is not exclusionary)
  • ✕ Symptomatic musculoskeletal conditions in the lower limbs that could impede measurement of efficacy for the target knee joint
  • ✕ Concomitant inflammatory disease or other conditions that affects the joints (eg, rheumatoid arthritis, metabolic bone disease, psoriasis, symptomatic chondrocalcinosis)

Where it's recruiting

California

Palo Alto · Sacramento

Louisiana

New Orleans

Maryland

Baltimore

Michigan

Ann Arbor

New York

The Bronx

Ohio

Akron · Columbus

Pennsylvania

Philadelphia

Rhode Island

East Providence

Texas

Houston · Plano

Wisconsin

Milwaukee

Source: ClinicalTrials.gov · NCT03588975 · last updated 2026-11-03